
Medicare drug price negotiations lowered out-of-pocket costs for some beneficiaries, but those reaching the annual Part D cap saw no direct savings.
Supplements and Featured Publications
about 24 years ago
Participating Facultyabout 24 years ago
New Directions for Type 2 Diabetes Mellitus Management





